Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NAT1 | P18440 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8828528 | 1.00 | HSD11B1 (0.61) | HSD11B1IKBKBPIM1PIM2METAP1 | |
| SCHEMBL5752280 | 1.00 | HSD11B1 (0.61) | HSD11B1IKBKBPIM1PIM2METAP1 | |
| SCHEMBL5753273 | 0.89 | HSD11B1 (0.64) | HSD11B1IKBKBPIM1PIM2METAP1 | |
| SCHEMBL5753271 | 0.89 | HSD11B1 (0.64) | HSD11B1IKBKBPIM1PIM2METAP1 | |
| SCHEMBL5754714 | 0.88 | HSD11B1 (0.62) | HSD11B1IKBKBPIM1PIM2METAP1 | |
| SCHEMBL11325672 | 0.81 | AKR1C3 (0.56) | PIM1PIM2NPC1NAT1PARP1 | |
| SCHEMBL15828902 | 0.81 | KMT2A (0.58) | HSD11B1PIM1PIM2NPC1ALDH1A1 | |
| SCHEMBL11325775 | 0.81 | CYP1A2 (0.59) | PIM1PIM2NPC1ALDH1A1NAT1 | |
| SCHEMBL8883177 | 0.81 | CYP1A2 (0.59) | PIM1PIM2NPC1ALDH1A1NAT1 | |
| SCHEMBL9139338 | 0.79 | MIF (0.48) | HSD11B1PARP1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485351-A4 | PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE 3-SUBSTITUTED LACTAMS BY ASYMMETRIC HYDROGENATION OF 3-ALKYLIDENELACTAMS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7015320-B2 | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1485351-A2 | PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE 3-SUBSTITUTED LACTAMS BY ASYMMETRIC HYDROGENATION OF 3-ALKYLIDENELACTAMS | Bristol-Myers Squibb Company (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040010139-A1 | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003079975-A2 | PROCESS FOR THE MANUFACTURE OF OPTICALLY ACTIVE 3-SUBSTITUTED LACTAMS BY ASYMMETRIC HYDROGENATION OF 3-ALKYLIDENELACTAMS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010139-A1 | Process for the manufacture of optically active 3-substituted lactams by asymmetric hydrogenation of 3-alkylidenelactams | MRPL21, LAS1L, OXA1L | HSD11B1 1362/4885IKBKB 2837/4885PIM1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.